Inhibition of MHC Class II Expression and Immune Responses by c-MIR
P reviously we reported a novel E3 ubiquitin ligase (E3), designated c-MIR, which targets B7-2 to lysosomal degradation by ubiquitination of its cytoplasmic tail (1) . c-MIR has been proposed to belong to a novel family of E3, designated as the modulator of immune recognition (MIR) 4 family, whose catalytic domain is a variant RING domain (RING-CH domain) (2) (3) (4) . MIR family proteins share a secondary structure and a catalytic domain as a variant RING domain, which is located at the N terminus (3) . MIR family proteins bind to the membrane through their hydrophobic domains located at the center and possess two intracellular regions. The initially discovered MIR family proteins are viral E3s: MIR1 and MIR2 of Kaposi's sarcoma-associated herpesvirus (KSHV), mK3 of murine ␥-herpesvirus 68, and m153R of myxomavirus (3, (5) (6) (7) (8) (9) . Each molecule targets a different set of Ag presentation-related molecules: CD1d and MHC class I (MHC I) for MIR1; B7-2, ICAM-1, CD1d, and MHC I for MIR2; MHC I for mK3; MHC I, CD4, and Fas for m153R (3, 5, 9 -12) .
It has been proposed that down-regulation of MHC I by viral E3s contributes to viral strategies for the evasion from host immunity. This idea emerged from an experiment, which was performed using genetically modified murine ␥-herpesvirus 68 (13) . First, an mK3-deficient virus, which is not able to down-regulate MHC I expression efficiently, was generated. The propagation of this mK3-deficient virus was not impaired in vitro, but fibroblasts infected with the mK3-deficient virus were more sensitive to Agspecific CTL clones than those infected with wild-type virus. In addition, in mice infected with the mK3-deficent virus, the efficiency of the latent infection in the spleen was reduced, and the frequency of virus-specific CTL was increased. Thus, at least, mK3 was clearly shown to function as an immune modulator that helps the virus to evade host immunity in vivo.
c-MIR was found as a functional and structural homolog of KSHV MIR1 and MIR2 by searching the public databases (1) . At present, its physiological function remains unknown. However, forced expression of c-MIR in B cell lines induces strong downregulation of B7-2 surface expression, suggesting its involvement in immune regulation in vivo. Furthermore, c-MIR has been shown to down-regulate the expression of transferrin receptor and Fas, an important molecule for the induction of apoptosis (14) . Again, the biological relevance of these findings remains unknown. Up to date, several mammalian E3s related to c-MIR have been characterized, and these mammalian E3s including c-MIR were termed MARCH (membrane-associated RING-CH) proteins, and c-MIR is now also known as MARCH VIII (14) .
The molecular machinery for MIR family protein-mediated down-regulation of target molecules is under intensive examination by several groups. As shown in the case of other families of E3, MIR family proteins also induce the ubiquitination through binding to target molecules (1) . The lysine residues in the cytoplasmic tail of target molecules have been identified as the sites for ubiquitination by MIR family proteins. In the most cases, the ubiquitination of cytoplasmic tail is thought to induce a rapid endocytosis and lysosomal degradation of the target molecules (15) . In contrast, mK3 encoded by murine ␥-herpesvirus 68, a member of MIR family, has been shown to induce the retrograde transport of MHC I at endoplasmic reticulum and finally degrade the targets at the proteasome (16) . There is no clear picture that explains why mK3 uses a different way for down-regulation of MHC I. As to the molecular mechanism for specific targeting by MIR family proteins, an experiment was performed (17) . Ganem and colleagues (11, 12, 17) showed that a chimeric MIR1 whose transmembrane regions were substituted by those of MIR2 was able to down-regulate B7-2 and ICAM-2, which are targets for MIR2 but not MIR1. This result suggests the involvement of transmembrane regions of MIR1 and MIR2 and the targets for substrate specificity.
B7-2 is well known as a costimulatory molecule in Ag presentation. B7-2-deficient mice have been reported to be resistant to the onset of autoimmune diseases (18) , suggesting that B7-2 might be a candidate target for immune therapy. Therefore, our previous observation led us to examine the attractive hypothesis that artificial manipulation of c-MIR expression might modulate immune responses in vivo.
In this report, we show that forced expression of c-MIR in APCs in vivo inhibits Ag presentation and prevents the onset of experimental autoimmune encephalomyelitis (EAE). Furthermore, we show that MHC class II (MHC II) is an additional target of c-MIR, and down-regulation of its surface expression depends on the presence of a single lysine residue in the cytoplasmic tail of ␤-chain of MHC II. These findings reveal an additional function of c-MIR and suggest c-MIR might potently regulate immune responses in vivo.
Materials and Methods

Transgene construction and generation of transgenic (Tg) mice
Murine c-MIR cDNA was obtained from total RNA of the spleen by RT-PCR. The sequence of the hemagglutinin (HA) epitope tag was introduced at the 3Ј terminus of cDNA by PCR. The resultant DNA fragment was inserted into a unique ClaI site of pDOI-6 vector, which was provided by C. Benoist and D. Mathis (Joslin Diabetes Center, Boston, MA) (19) . The linearized DNA was microinjected into the pronuclei of fertilized eggs from BDF 1 mice, and Tg founders were backcrossed onto the C57BL/6 background at least six times. In all experiments, nontransgenic littermates were used as control mice. All mice were maintained under specific pathogen-free conditions according to the instructions of Kobe University School of Medicine and RIKEN (The Institute of Physical and Chemical Research) guidelines and used for analysis at 8 -12 wk of age.
Histological analysis
Various organs were removed and fixed in 10% formalin/PBS. Frozen sections were prepared and stained with H&E. Serial frozen sections were stained with anti-HA Ab, and the signal was enhanced using the TSA system (tyramide signal amplification; Invitrogen Life Technologies). For double staining analysis, the frozen sections were fixed with cold acetone, stained with anti-HA Ab using TSA system, and then each section was stained with indicated Abs.
Immunofluorescence microscopy
Cells were fixed with 4% paraformaldehyde/PBS for 15 min and cold acetone for 15 min. Stained tissue sections or fixed cells were mounted in mounting media (Vector Laboratories) and examined by a DP-70 Immunofluorescence digital camera (Olympus).
Quantification by real-time RT-PCR
For the quantification of c-MIR mRNA level, TaqMan Gene Expression Assays (Applied Biosystems) was used. Total RNA was extracted using an RNeasy kit (Qiagen) from the indicated cells prepared from each mouse, and reverse-transcribed using the SuperScript RT kit (Invitrogen Life Technologies) according to the manufacturer's protocol. Synthesized cDNAs were transferred into TaqMan Universal PCR Master Mix containing a FAM-labeled TaqMan probe and specific primers for murine c-MIR, and subsequent PCR amplification was performed. The cycle threshold number, at which amplification entered exponential phase, was determined in each sample by using ABI PRISM 7000 sequence detection system (Applied Biosystems). Relative quantitation was performed using comparative Ct method. All results were normalized to an internal control: the 18 S mRNA. For the quantitative analysis of the expression of I-A ␤-chain and invariant chain (Ii), we used the QuantiTect SYBR Green PCR kit (Qiagen). First-strand cDNA was generated from the B cells of control or c-MIR Tg mice, and short (ϳ150-bp) fragment from MHC II or Ii cDNA was amplified by PCR with each specific set of primers. The intensity of incorporated SYBR Green was monitored by using an ABI PRISM 7000 sequence detection system (Applied Biosystems). The expression level of ␤-actin was determined for normalization of the data.
Immunoblots, metabolic labeling, and immunoprecipitation
Cells were lysed with RIPA buffer (0.15 M NaCl, 1% Nonidet P-40, 0.1% SDS, and 50 mM HEPES buffer (pH 8.0)) containing protease inhibitors, and the supernatants were cleared by centrifugation. Whole cell lysates were subjected to immunoprecipitating and/or serial immunoblotting as indicated for each experiment. Immunoprecipitation was performed with the indicated Ab together with 20 l of protein A/G-agarose beads (Santa Cruz Biotechnology). For PNGase-F digestion, washed immunoprecipitates were resuspended in 50 l of 1ϫ denaturing buffer (0.5% SDS, 1% 2-ME), heated for 10 min at 100°C and incubated for 1 h at 37°C with 1 l of PNGase-F (New England Biolabs). For metabolic labeling, cells were incubated in medium containing 50 Ci of [
35 S]methionine and [ 35 S]cysteine (PerkinElmer) for 6 h. Labeled protein samples were extracted and precipitated with 20 l of protein A/G-agarose beads (Santa Cruz Biotechnology). For pulse-chase analysis, cells were labeled for 30 min, chased for the indicated time, and labeled proteins were extracted with Nonidet P-40 buffer (0.5% Nonidet P-40, 300 mM NaCl, and 50 mM Tris buffer (pH 7.4)) containing protease inhibitors.
Cell surface biotinylation and immunoprecipitation
Pulse-labeled A20 cells at each chase time were incubated with NHS-SSbiotin (succinimidyl 2-(biotinamido)-ethyl-1,3Ј-dithiopropionate, 2 mg/ml; Pierce) in PBS for 2 min on ice. Biotinylated and labeled proteins were extracted by Nonidet P-40 buffer and precipitated with MKD6 Ab. Precipitated samples were eluted from the protein A/G-Sepharose beads by boiling for 2 min in 2% SDS in PBS. Eluted biotinylated proteins were precipitated with streptavidin-agarose (Pierce) and analyzed by SDS-PAGE. 
Flow cytometry analysis and Abs
Cell preparation
Immature dendritic cells (DCs) were prepared by culturing bone marrow (BM) cells obtained from each mouse with GM-CSF (20 ng/ml) (PeproTech) for 8 days. Mature DCs were generated from immature DCs by stimulation with LPS (1 g/ml) (Sigma-Aldrich) for 24 h. CD4 T cells, T cells, B cells, splenic DCs, and splenic macrophages were purified from the spleens of mice using the MACS system (Miltenyi Biotec). CI:A3-1 biotinconjugated anti-F4/80 Ab for macrophages, 30-H12 biotin-conjugated anti-CD90.2/Thy-1.2 Ab for T cells, RA3-6B2 biotin-conjugated anti-CD45R Ab for B cells were obtained from eBioscience to prepare each cells. CD11c microbeads for preparation of DCs were obtained from Miltenyi Biotec. The cell purity of each type of cells isolated by MACS system was routinely ϳ95% pure. Thymic stromal cells were isolated by digestion with collagenase/dispase (Roche) as reported previously (20) . 
Analysis of Ag presentation
EAE induction
Generation of BM chimeras
A total of 15 ϫ 10 6 BM cells was injected into lethally irradiated (8.5 Gy) mice. Mice were used for the experiments 8 wk after reconstitution.
ELISPOT assay
To determine the frequency of autoreactive T cells among CD4 T cells, splenic CD4 T cells were cultured with irradiated syngenic splenocytes in the presence of MOG 35-55 in 96-well ELISPOT kits (R&D Systems). IFN-␥-or IL-2-producing CD4 T cells were detected according to the manufacturer's protocol.
Plasmid construction
Murine c-MIR cDNA was subcloned into pTracer or pEF-1 vector (Invitrogen Life Technologies). I-A d ␤-chain cDNA was obtained from total RNA of the spleen by RT-PCR and subcloned into pTracer or pEF-1 vector. Substitutions were generated into the cytoplasmic tail of the I-A d ␤-chain and the RING-variant domain of the murine c-MIR by PCR-based mutagenesis (Promega). To introduce a FLAG epitope tag, each cDNA was subcloned into p3XFLAG-CMV vector (Sigma-Aldrich).
Cell culture and transfection A20, A20.2J, M12 C3, and M12 B6 cells were grown in RPMI 1640 with 10% FCS. 293T cells were grown in DMEM with 10% FCS. M12 C3 cells were kindly provided by O. Kanagawa (RIKEN, Yokohama, Japan) (22, 23) . For transient assays, expression plasmid DNAs were introduced by electroporation at 260 V and 975 F in serum-free RPMI 1640 medium. To select stable transformants, 2 mg/ml G418 (Sigma-Aldrich) was added 48 h posttransfection, and cells were maintained in selective medium for 3-6 wk. Also, each plasmid DNA was transfected into 293T cells using the Fugene 6 reagent (Roche).
Statistics
Clinical scores were analyzed with the nonparametric Mann-Whitney U test. T cell proliferation data and flow cytometric data were analyzed with Student's t test. Values of p Ͻ 0.05 were considered significant.
Results
Generation of c-MIR Tg mice
To examine the immune regulatory functions of c-MIR, we generated genetically modified mice in which HA-tagged c-MIR was expressed under an Ii promoter using pDOI6, which allows examined molecules to be expressed in APCs. We thereby finally generated two lines of Tg mice: no. 64 and no. 65, in which the expression of exogenous c-MIR protein could be visualized in situ by immunohistochemistry. Fig. 1 , A and C, shows the expression of HA-tagged c-MIR in the spleen and the thymus of mouse no. 64. This specific expression profile was confirmed by immunohistochemical and immunoprecipitation analysis (Fig. 1 , B and D). As shown in Fig. 1B , the expression of HA-tagged c-MIR was observed in most of the B cells and in part of DCs. To confirm that c-MIR is overexpressed in APCs in the spleen of c-MIR Tg mice, quantitative real-time PCR analysis was performed. In this experiment, we generated a pair of primers to amplify one part of the open reading frame of endogenous c-MIR so that this assay can detect endogenous c-MIR mRNA as well as exogenous mRNA. As we reported in previous work (1), in control littermates, the expression level of endogenous c-MIR mRNA was low in B and T cells, whereas macrophages and DCs moderately expressed c-MIR mRNA (Fig. 1E) . In c-MIR Tg mice, the expression level of c-MIR mRNA was remarkably increased in macrophages, DCs, and B cells and was slightly increased in T cells, compared with littermate controls (Fig. 1E) . Thus, in c-MIR Tg mice, the expression of c-MIR was increased predominantly in APCs. The growth of c-MIR Tg mice was not impaired, and there were no significant differences in the size and shape of the organs including the lymphoid tissues (Fig. 1 , A and C). In contrast, there were small, but statistically significant differences in the proportions of splenic B and T cells (Fig. 1F) ; the percentage of CD3 ϩ cells in c-MIR Tg mice was decreased (34.9 Ϯ 2.5% in c-MIR Tg vs 41.9 Ϯ 1.9% in control littermates; p Ͻ 0.05; n ϭ 6), and the percentage of B220 ϩ cells in c-MIR Tg mice was contrastingly increased (50.1 Ϯ 1.6% in c-MIR Tg vs 46.2 Ϯ 3.2% in control littermates; p Ͻ 0.05; n ϭ 6). These findings were exactly the same in two lines of c-MIR Tg mice (data not shown).
Expression of B7-2 is significantly inhibited in the BMDCs generated from c-MIR Tg mice
To confirm that exogenously expressed c-MIR is functionally active in Tg mice, we examined the expression level of B7-2 in BMDCs generated from c-MIR Tg mice and control littermates.
Both types of BM cells differentiated into CD11c
ϩ cells, showing that normal development of BM cells occurred in c-MIR Tg mice ( Fig. 2A) . However, we found that up-regulation of B7-2 upon LPS stimulation was significantly inhibited in BMDCs generated from c-MIR Tg mice by measuring the mean fluorescence intensity (MFI) of B7-2; MFI of B7-2 in LPS-treated BMDCs (mature DC) generated from c-MIR Tg was lower than that in mature DC generated from control littermates (96 Ϯ 11.5 vs 532 Ϯ 17.4, respectively; p Ͻ 0.01; n ϭ 3) (Fig. 2B) . Also, this inhibition was confirmed by measuring the proportion of the cells whose B7-2 expression level is high (above 10 2 as its fluorescence intensity in Fig. 2B ) compared with total LPS-treated BMDCs. The percentage of B7-2 high cell in total LPS-treated BMDCs from c-MIR Tg mice was significantly lower than that in total LPS-treated BMDCs from control littermates (42.6 Ϯ 2.8% vs 88.7 Ϯ 3.6%, respectively; p Ͻ 0.01; n ϭ 3). This inhibition was specific to B7-2 because up-regulation of B7-1 and MHC I expression were not significantly inhibited (Fig. 2B ). The expression of exogenous c-MIR was confirmed in immature BMDCs and in LPS-stimulated BMDCs of c-MIR Tg mice by immunoprecipitation analysis (Fig. 2C) .
Forcibly expressed c-MIR suppresses the function of APCs
The results shown in Fig. 2B suggest that BMDCs with forcibly expressed c-MIR are not able to present the Ags to T cells efficiently. To this end, we performed MLR assay. BMDCs from c-MIR Tg mice or control littermates were stimulated with LPS for 24 h, irradiated and mixed with allogenic CD4 T cells. The ability of allogenic T cells to proliferate was analyzed. As shown in Fig. 2D , the ability of c-MIR Tg mice-derived DCs to stimulate allogenic T cells was lower than the ability of control littermate-derived DCs. To confirm this suppression of the Ag-presenting activity, we examined the ability of Ag-specific presentation using OT-II Tg mice-derived T cells, which recognize OVA peptide loaded by the I-A b molecule. Again, the ability of c-MIR Tg micederived BMDCs to stimulate OT-II T cells was lower than ability found in control littermates-derived BMDCs. Next, to examine whether c-MIR functions as an immune suppressor in other cells, we generated a B cell line in which c-MIR is forcibly expressed under the control of the elongation factor EF1␣ promoter. A20.2J cells were chosen for this purpose because these cells express B7-2 at moderate levels ( Fig. 2E) (24) . A20.2J cells with forced expression of c-MIR were mixed with a Th1 clone, 42-6A, which recognizes OVA 323-339 peptide presented by the I-A d molecule. As shown in Fig. 2F , the c-MIR-expressing A20.2J cells were not able to stimulate 42-6A cells efficiently in the presence of either OVA polypeptide or OVA 323-339 peptide.
Forcibly expressed c-MIR prevents the onset of EAE
As shown in Fig. 2, D and F, c-MIR is able to inhibit the function of APCs efficiently, suggesting that forced expression of c-MIR might inhibit T cell-mediated immunity in vivo. To test this hypothesis, we chose EAE, an autoimmune disease caused by the occurrence of autoreactive CD4 T cells against myelin Ags and which can be prevented by inhibition of APCs (25) . The clinical score of control littermates was elevated to 3 at 15-18 days. In contrast, c-MIR Tg mice did not show any clinical symptoms during the entire observation period (Fig. 3A) . To examine the frequency of autoreactive T cells among CD4 T cells, we collected CD4 T cells from the spleens of control littermates or c-MIR Tg mice 10 days after EAE induction and measured the frequency of autoreactive CD4 T cells by ELISPOT. As we expected, the frequency of autoreactive CD4 T cells was remarkably reduced in the spleen of the c-MIR Tg mice (Fig. 3A) . During analysis of autoreactive CD4 T cells, we found that the total number of splenic CD4 T cells in c-MIR Tg mice was only about half of that in control littermates (data not shown). These results suggest that the 
. Therefore, we assessed the development of T cells in the thymus and the spleen of c-MIR Tg mice. In the spleens of c-MIR Tg mice, the percentage of CD4 T cells was slightly lower than that of control littermates, but the percentage of CD8 T cells was not remarkably different between the two types of mice (Fig. 3B) . The percentage of CD4 T cells was more significantly decreased in the thymus (Fig. 3B) . Furthermore, the frequency of matured CD4 single-positive thymocytes, but not that of matured CD8 singlepositive thymocytes, was significantly reduced in the thymus of c-MIR Tg mice (Fig. 3B ). These results demonstrate that the development of CD4 T cells is selectively impaired in c-MIR Tg mice.
We then assessed whether impaired CD4 T cell development in c-MIR Tg mice is due to intrinsic defects of blood-derived hemopoietic cells, including T cells, or caused by a nonhemopoietic microenvironment, including the thymic environment, through adoptive transfer experiments. BM cells from control littermates were transplanted into lethally irradiated c-MIR Tg mice (Cont Ͼ c-MIR Tg) or control littermates (Cont Ͼ Cont). Moreover, BM cells from c-MIR Tg mice were transplanted into lethally irradiated control littermates (c-MIR Tg Ͼ Cont). As shown in Fig. 3C , the development of CD4 single-positive thymocytes was impaired in control littermates transplanted into lethally irradiated c-MIR Tg mice, but development was normal in thymocytes in c-MIR Tg mice transplanted into lethally irradiated control littermates, compared with cells in control littermates transplanted into lethally irradiated control littermates, suggesting that an impaired CD4 T cell development in c-MIR Tg mice was probably due to the defects in the nonhemopoietic environment, such as the thymic microenvironment.
Next, we investigated the phenotypes of splenic DCs as physiologic APCs in c-MIR Tg mice. As shown in Fig. 3D , the surface expression of B7-2, but not that of B7-1 and MHC I, was significantly down-regulated on splenic DCs obtained from LPS-treated c-MIR Tg mice; the MFI of B7-2 in DCs obtained from LPStreated c-MIR Tg mice (LPSϩ) was lower than that in DCs obtained from LPS-treated control littermates (20.4 Ϯ 3.7 vs 47.7 Ϯ 6.6, respectively; p Ͻ 0.01; n ϭ 3). In addition, c-MIR Tg-derived splenic DCs were not able to stimulate OT-II CD4 T cells efficiently (Fig. 3E) . Consistent with the results obtained from experiments with BMDCs (Fig. 2, B and D) , the function of physiologic APCs was impaired in c-MIR Tg mice, giving rise to the question as to whether inhibition of Ag presentation contributes to the prevention of EAE induction by c-MIR. To address this question, we examined the susceptibility of cells in c-MIR Tg mice transplanted into lethally irradiated control littermates used in Fig. 3C to the induction of EAE because in these mice, the CD4 T cell development is normal and physiologic APCs are thought to be derived from c-MIR Tg mice. As shown in Fig. 4, A and B , c-MIR Tg mice transplanted into lethally irradiated control littermates were resistant to the induction of EAE to some extent, and the frequency of autoreactive CD4 T cells was significantly reduced in the spleen of these mice, compared with frequency of cells in control littermates transplanted into lethally irradiated control littermates. In addition in c-MIR Tg mice transplanted into lethally irradiated control littermates, the surface expression of B7-2 was significantly downregulated on splenic DCs; the MFI of B7-2 in DCs obtained from LPS-treated c-MIR Tg mice transplanted into lethally irradiated control littermates (LPSϩ) was lower than that in DCs obtained from LPS-treated control littermates transplanted into lethally irradiated control littermates (58.7 Ϯ 0.5 vs 98.9 Ϯ 16.9, respectively; p Ͻ 0.05; n ϭ 3) (Fig. 4C) . Furthermore, splenic DCs derived from c-MIR Tg mice transplanted into lethally irradiated control littermate were not able to stimulate OT-II CD4 T cells efficiently (Fig. 4D) , indicating that physiologic APCs were derived from c-MIR Tg mice. Thus, these results suggest that inhibition of Ag presentation partially contributes to the prevention of EAE induction in c-MIR Tg mice.
MHC II molecule is an additional target of c-MIR
In c-MIR Tg mice, the development of CD4 T cells was significantly impaired presumably due to the defects in the nonhemopoietic environment, such as the thymic microenvironment. Also, as shown in Fig. 2F , the Ag recognition by 42-6A Th1 clone was more strongly inhibited by c-MIR, compared with that by primary/ naive T cells, OT-II T cells. These findings cannot be explained by the inhibition of B7-2 because B7-2-deficient mice do not show any abnormalities in the development of CD4 T cells (26) , and T cell clones are thought to be less dependent on costimulation for optimal responses than primary T cells. In contrast, MHC II-deficient mice have been reported to show impaired development of CD4 T cells and strongly reduced T cell immunity (27) . Therefore, we examined the level of MHC II expression in the thymus in c-MIR Tg mice. Histochemical analysis of the thymus revealed that the expression of MHC II was significantly down-regulated in c-MIR Tg mice (Fig. 5A) . Specific down-regulation of MHC II expression was confirmed by FACS analysis of thymic EpCAM ϩ epithelial cells (Fig. 5B) . Interestingly, FACS analysis of thymic epithelial cells showed two populations of EpCAM ϩ epithelial cells; one population whose MHC II expression was remarkably down-regulated, and another population whose MHC II expression was not significantly inhibited.
To confirm the down-regulation of MHC II expression by c-MIR in vivo, we next examined the expression of MHC II in the spleen. As observed in the thymus, down-regulation of MHC II expression was observed in the B cell follicles (data not shown). In addition, double staining analysis with anti-MHC II and anti-HA Abs showed that the regions brightly stained with anti-HA Ab showed low expression of MHC II, but the regions that were not stained with anti-HA Ab showed high expression of MHC II in the same B cell follicle, suggesting that exogenous expression of c-MIR suppressed the expression of MHC II in vivo (Fig. 5C ). This finding was confirmed by FACS analysis of the splenocytes (Fig.  5D ). Given our previous report that showed c-MIR induces rapid degradation of B7-2, down-regulation of MHC II is also speculated to occur at the posttranscriptional level. Therefore, to rule out the possibility of transcriptional alteration of the MHC II gene and its related genes, we examined the mRNA level of I-A ␤-chain gene and Ii gene in the splenic B cells by quantitative real-time PCR. As we expected, there was no significant difference in the amount of I-A ␤ mRNA and Ii mRNA between c-MIR Tg mice and control littermates (Fig. 5E) . Finally, we examined whether c-MIR directly influenced the surface expression of MHC II using A20 cells, a murine B cell line. c-MIR was expressed by electroporation of a vector DNA that expresses both enhanced GFP and c-MIR from different promoters. The transfected A20 cells were stained with anti-MHC II or anti-MHC I Ab and analyzed by two-color flow cytometry. This analysis showed that forced expression of c-MIR down-regulated the surface expression of MHC II but not MHC I (Fig. 5F) .
A single lysine residue in the cytoplasmic tail of MHC II ␤-chain is responsible for its down-regulation
The mature MHC II molecule is a heterodimer that consists of ␣-chain and ␤-chain. In addition, Ii molecule is a third component of the immature MHC II molecule (28) . Therefore, we examined which components are targeted by c-MIR. First, the amount of Ii molecule was examined by immunoblot analysis in parental and c-MIR-overexpressing A20.2J cells. This analysis revealed that the amount of Ii molecule was not reduced by c-MIR (Fig. 6A) . We and other groups previously showed that lysine residues located in the cytoplasmic tail of targets were responsible for down-regulation of targets by viral and mammalian E3s (1, 2, 5) . Examination of the peptide sequences of the ␣-and ␤-chains of MHC II molecule revealed that the ␤-chain but not the ␣-chain of I-A has one lysine residue in its cytoplasmic tail, leading us to focus on the (Fig. 6B) .
Ubiquitination and degradation of MHC II by c-MIR
Next, we examined whether c-MIR induces ubiquitination and degradation of MHC II. To address this question, we constructed an assay system using a FLAG-tagged I-A ␤-chain in which a FLAG epitope was fused to the N terminus of the extracellular region of I-A ␤-chain. I-A ␣-chain and FLAG-tagged I-A ␤-chain were coexpressed in 293T cells, and the surface expression of MHC II was analyzed by flow cytometry. As shown in Fig. 7A , M5/114.15.2 Ab recognized MHC II molecules that were reconstituted by I-A ␣-chain and FLAG-tagged I-A ␤-chain on the cell surface, suggesting that the reconstituted MHC II molecules were correctly folded and transported to the cell surface. Moreover, c-MIR was able to down-regulate the surface expression of MHC II molecules reconstituted with I-A ␣-chain and FLAG-tagged I-A ␤-chain, but not with I-A ␣-chain and FLAG-tagged I-A ␤-chain whose K225 was mutated to arginine. c-MIR mutant form whose cysteine residues in RING-variant domain were mutated to serine (c-MIR RING-variant mt) did not remarkably down-regulate the surface expression of MHC II reconstituted with I-A ␣-chain and FLAG-tagged I-A ␤-chain. Based on these findings, we concluded that this assay system is able for use in further analysis.
c-MIR or c-MIR RING-variant mt was coexpressed with I-A ␣-chain and FLAG-tagged I-A ␤-chain in 293T cells, and FLAGtagged I-A ␤-chain was precipitated with anti-FLAG M2 Ab. The precipitated samples were deglycosylated by incubation with PNGase-F and examined by immunoblot analysis with anti-FLAG Ab or anti-ubiquitin Ab. As shown in Fig. 7B above the band corresponding to FLAG-tagged I-A ␤-chain, additional bands were detected with anti-FLAG Ab in c-MIR-expressed sample, but not in c-MIR RINGvariant mt-expressed samples. In addition, all additional bands (Fig.  7B, left) were also detected with anti-ubiquitin Ab (Fig. 7B, right with  asterisks) , showing that c-MIR induced ubiquitination of the I-A ␤-chain. To examine whether K225 of I-A ␤-chain is responsible for its ubiquitination, c-MIR or c-MIR RING-variant mt was coexpressed with I-A ␣-chain and FLAG-tagged I-A ␤-chain whose K225 was mutated to arginine in 293T cells, and precipitated FLAG-tagged I-A ␤-chain with mutated K225 to arginine was subjected to immunoblot analysis with anti-FLAG Ab and anti-ubiquitin Ab. As shown in Fig.  7B , FLAG-tagged I-A ␤-chain whose K225 was mutated to arginine was not ubiquitinated by c-MIR. To confirm c-MIR-mediated ubiquitination of I-A ␤-chain, HA-tagged ubiquitin was coexpressed with c-MIR or its mutant form, FLAG-tagged I-A ␤-chain or its mutant form, and I-A ␣-chain as indicated in Fig. 7C , and the ubiquitination status of FLAG-tagged I-A ␤-chain was examined as in Fig. 7B . In this experiment, the status of ubiquitination was examined by immunoblot analysis with anti-HA Ab instead of anti-ubiquitin Ab. As shown in Fig. 7C , only when wild-type c-MIR, I-A ␣-chain and wildtype I-A ␤-chain were coexpressed, the ubiquitinated form of FLAGtagged I-A ␤-chain was detected (Fig. 7C, asterisks) . As shown in Fig.  7D , the expression levels of c-MIR and its mutant form were equivalent in each experiment. Thus, these results clearly demonstrate that c-MIR ubiquitinates the lysine residue at position 225 in the I-A d ␤-chain. Interestingly, however, unless the precipitated samples were treated with PNGase-F, we could not detect the band corresponding to a monoubiquitinated form of I-A ␤-chain, which was shown as an ϳ40-kDa band above the band of FLAG-tagged I-A ␤-chain in Fig.  7B (data not shown) . These findings suggest that glycosylation might inhibit the recognition of the monoubiquitinated form of I-A ␤-chain by anti-ubiquitin Ab; FK-2, and in the case of glycoproteins, the treatment of deglycosylation might help to detect faint bands corresponding to their ubiquitinated form. This finding seems to be important when looking for endogenous MHC II molecules ubiquitinated in vivo.
Next, we examined whether c-MIR enhances degradation of MHC II in this system. I-A ␤-chain or I-A ␤-chain whose K225 was mutated to arginine was coexpressed with I-A ␣-chain and c-MIR in the 293T cells. The transfected cells were pulse-labeled with [
35 S]methionine and [ 35 S]cysteine and chased for the indicated periods of time. As shown in Fig. 7E, I -A ␤-chain was faster degraded by c-MIR than I-A ␤-chain whose K225 was mutated to arginine. Taken together, these results suggest that c-MIR enhances degradation of MHC II through ubiquitination at the K225 of I-A ␤-chain.
Rapid endocytosis of MHC II by c-MIR
Next, we examined how c-MIR influences the assembly, export and traffic of MHC II molecules in APCs. To this end, we used A20 cells because this cell line expresses a large amount of MHC II as shown in Fig. 5F , and the mechanism of MHC II transport in this cell line is well characterized (29) . A20 cells were engineered to have stable and excess expression of c-MIR by electroporation (c-MIR cells) and compared with empty vector-transfected A20 cells (control cells). c-MIR cells and control cells were pulse-labeled with [
35 S]methionine and [ 35 S]cysteine and chased for the indicated periods of time. At the end of the chase periods, pulselabeled proteins were immunoprecipitated with MKD6 anti-I-A d ␤-chain mAb, which preferentially recognizes mature ␣␤ dimers, and precipitated samples were analyzed by SDS-PAGE without boiling the samples before electrophoresis. As shown in Fig. 8A , in both control cells and c-MIR cells, completely assembled MHC II molecules, which consisted of ␣-chain and ␤-chain, were equally detected at 60 min of chase, and the amount of these was not remarkably different. Also, bands corresponding to SDS-stable compact dimers, which reflect peptide-loaded ␣␤ dimers, were equally detected at 60 or 180 min of chase in both control and c-MIR cells. Consistent with the results obtained from a reconstitution system in 293T cells, in c-MIR cells, the amount of mature ␣␤ dimers was decreased at 360 min of chase, compared with in control cells. These results clearly demonstrate that c-MIR enhances the degradation of MHC II molecules without alternation of its translation, assembly and peptide-loading process in APCs.
Next, we examined whether c-MIR interferes with the transport of mature ␣␤ dimers to the cell surface. c-MIR cells and control cells were pulse-labeled as in Fig. 8A , and at the end of the chase periods, the labeled cells were biotinylated with a membrane-impermeable reagent. The pulse-labeled and biotinylated MHC II molecules were immunoprecipitated with MKD6, followed by purification with a streptavidin-agarose. Purified samples were boiled in sample buffer and analyzed by SDS-PAGE. As shown in 
Discussion
In this report, we demonstrated that force-expressed c-MIR functions as a potent immune modulator in vivo and in vitro, and that MHC II is an additional target of c-MIR. Genetically modified mice in which c-MIR is overexpressed in APCs showed marked immune defective phenotypes, such as resistance to the onset of autoimmune disease or impaired CD4 T cell development. Consistent with these phenotypes, surface expression of MHC II was significantly down-regulated on thymic epithelial cells and peripheral APCs in c-MIR Tg mice. Also, forced expression of c-MIR down-regulated the expression of MHC II, and its down-regulation depended upon ubiquitination of a single lysine residue in the cytoplasmic tail of I-A ␤-chain. To our knowledge, c-MIR is the first example of an E3 that is capable of targeting MHC II. Hence, further analysis of c-MIR might provide new insight into the molecular mechanism of Ag presentation.
At present, the physiological role of c-MIR is as yet unknown. However, there is indirect evidence that c-MIR might be a physiological immune modulator in vivo. We previously showed that forced expression of c-MIR down-regulates the expression of B7-2 and that c-MIR is expressed in human monocyte-derived DCs (1) . In this study, we showed that the expression of MHC II was significantly inhibited by c-MIR in APCs, and that c-MIR was moderately expressed in splenic macrophages and splenic DCs, which are physiological APCs in vivo. Furthermore, we found that during LPS-induced maturation of DCs, the expression of c-MIR was down-regulated, whereas the surface expression of B7-2 and MHC II were increased remarkably (our unpublished data). In addition, Shortman and colleagues (30) reported that immature DCs degrade MHC II-peptide complexes much faster than the matured DCs. Based on these findings, we propose the hypothesis that c-MIR might function as a modulator of MHC II expression in immature DCs. To examine this hypothesis, we are presently generating c-MIR-deficient mice.
Our results showed that forced expression of c-MIR strongly prevented the onset of EAE. As shown in Fig. 3 , the development of CD4 T cells and the ability of splenic DCs to present Ags were remarkably impaired in c-MIR Tg mice, suggesting that both factors contribute to complete prevention of EAE by c-MIR. We speculated that the latter factor partially contributes to the prevention of EAE, based on results obtained from experiments with a BM chimera (in c-MIR Tg mice transplanted into lethally irradiated control littermates). In c-MIR Tg mice transplanted into lethally irradiated control littermates, CD4 T cells developed normally, presumably due to normal expression of MHC II in the thymus (see Fig. 3C ), whereas peripheral APCs were derived from c-MIR Tg and failed to present Ags efficiently (Fig. 4D ). As shown in Fig.  4A , we found that the induction of EAE was partially prevented in c-MIR Tg mice transplanted into lethally irradiated control littermates. If impaired development of CD4 T cells was the main reason for the prevention of EAE, prevention would not be observed in this mouse model because CD4 T cell development is normal in this BM chimera judged by the expression profile of surface markers. However, this hypothesis should be considered more cautiously because the expression of exogenous c-MIR was faintly detected in samples from splenic T cells in c-MIR Tg mice (see Fig. 1, D and E) . In this connection, we found that an induced proliferation of splenic CD4 T cell by anti-CD3 Ab was significantly reduced in c-MIR Tg mice (our unpublished observation). This finding may reflect not only the impaired development of CD4 T cells, but also some other functional defects of CD4 T cells caused by a faint expression of exogenous c-MIR in these mice. However, anti-CD3 Ab-induced proliferation of CD4 T cells from c-MIR Tg mice transplanted into lethally irradiated control littermates was equivalent to that of control littermates transplanted into lethally irradiated control littermates (our unpublished observation). Because mature CD4 T cells of c-MIR Tg mice transplanted into lethally irradiated control littermates are thought to be derived from c-MIR Tg mice, a faint expression of exogenous c-MIR is probably present in the mature CD4 T cells of this BM chimera. Therefore, this amount of exogenous c-MIR protein is unlikely to influence the function of mature CD4 T cells. Thus, so far, we do not have any clear evidences that reject our hypothesis.
Besides the two factors we have described, uncharacterized effects of forcibly expressed c-MIR on the immune system might contribute to the complete prevention of EAE by c-MIR. Indeed, we found an increased population of splenic B cells in c-MIR Tg mice; this population consisted of IgM low IgD low B220 ϩ cells (our unpublished observation). In I-A ␤-chain-deficient or B7-2-deficient mice, B cell development was reported to be normal (26, 27) . In contrast, an increased percentage of IgM high IgD low B220 ϩ cells was reported in the spleen of I-A ␣-chain or Ii-deficient mice (31) . Thus, this finding cannot be explained by findings in MHC II or Ii-deficient mice, indicating that forced expressed c-MIR has other functions than down-regulation of MHC class II and B7-2. Because recent evidence suggests that B cells contribute to EAE induction (32), a detailed analysis of B cell function in c-MIR Tg mice is necessary to understand the detailed mechanisms for c-MIR-mediated prevention of EAE. As shown in Fig. 5B in control littermates , there are two populations of EpCAM ϩ epithelial cells; one population with high expression of MHC II and the other in which MHC II is expressed moderately. These results are consistent with the previous reports by Boyd and colleagues (20) , but at this moment, the cellular origins of these two populations remain unknown. Moreover, remarkable down-regulation of MHC II expression was observed only in the population whose MHC II expression level is moderate. This heterogeneous down-regulation was also observed in splenic B cells, as is shown in Fig. 5D . These findings might reflect the activity of the promoter used to generate c-MIR Tg mice. Indeed, Mathis and colleagues (19) reported that the expression level of Ii-moth cytochrome c chimeric molecule driven by this promoter was heterogeneous in IgM-positive cells, compared with that of endogenous Ii molecules. Thus, the activity of this promoter might be different from that of an authentic promoter for Ii molecules in some APCs, and this might be the cause of the unexpected heterogeneous down-regulation of MHC II in vivo.
Recently, several mammalian E3s related to c-MIR have been characterized, and these mammalian E3s including c-MIR were termed MARCH proteins, and c-MIR is now also known as MARCH VIII (14) . Among MARCH proteins, there is a closely related molecule to c-MIR, MARCH I. c-MIR and MARCH I have 63% amino acid identity and share the same secondary structure and the same positioning of the catalytic domain that is a variant RING domain. Especially, within their two helical transmembrane regions, MARCH I exhibits 88% amino acid identity as compared with c-MIR. Because the transmembrane regions of MIR family proteins are thought to determine the specificity for targeting (17) , one would expect MARCH I to target MHC II and B7-2 molecules as well, and there is a possible functional redundancy of c-MIR and MARCH I. Indeed, preliminary data obtained in our laboratory showed that the forced expression of MARCH I down-regulates the expression of MHC II, and also that MARCH I is expressed in APCs. In addition, Fruh and colleagues (14) and Cadwell and Coscoy (4) demonstrated the down-regulation of B7-2 by MARCH I. Given the apparent functional similarity of c-MIR and MARCH I, mouse models deficient in both molecules might constitute a powerful strategy to explore the physiological function of c-MIR.
Finally, given the striking effect of c-MIR overexpression on the immune system, manipulation of the function and/or expression of c-MIR might be used as a strategy for artificial immune modulation in vivo. At present, there are several projects that are attempting to identify and produce the novel subsets of DCs that induce immunological tolerance (33) . These DCs, which have been designated as tolerogenic DCs, or regulatory DCs show a very limited capability of Ag presentation (33, 34) . As shown in Fig. 2 , c-MIR Tg-derived BMDCs did not present several Ags to T cells efficiently, suggesting that APCs forcibly expressing c-MIR might function as tolerogenic DCs. Preliminary experiments in our group showed that allogenic T cells stimulated with c-MIR Tg-derived mature BMDCs were not able to proliferate efficiently upon stimulation when compared with control littermate mice-derived BMDCs, whereas T cell responsiveness was improved by adding an excess amount of IL-2. Therefore, we are now investigating possible applications of c-MIR for immune tolerance induction.
